CRIS Current Research Information System

CALZA, LEONARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.344
EU - Europa 8.527
AS - Asia 3.322
AF - Africa 475
SA - Sud America 30
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
Totale 21.710
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.327
GB - Regno Unito 2.784
DE - Germania 1.200
CN - Cina 1.193
UA - Ucraina 1.067
IT - Italia 1.046
SE - Svezia 966
VN - Vietnam 728
SG - Singapore 724
IN - India 507
FR - Francia 377
RU - Federazione Russa 367
IE - Irlanda 332
ZA - Sudafrica 199
EE - Estonia 175
TG - Togo 119
SC - Seychelles 91
JP - Giappone 75
BG - Bulgaria 53
JO - Giordania 39
CI - Costa d'Avorio 36
CH - Svizzera 35
FI - Finlandia 33
NG - Nigeria 24
GR - Grecia 22
LB - Libano 20
BE - Belgio 18
NL - Olanda 16
BR - Brasile 12
CL - Cile 10
CA - Canada 9
AU - Australia 8
ES - Italia 7
MX - Messico 7
UZ - Uzbekistan 7
IR - Iran 6
RO - Romania 6
AT - Austria 5
PH - Filippine 5
PT - Portogallo 5
TR - Turchia 5
EU - Europa 4
AR - Argentina 3
CZ - Repubblica Ceca 3
HK - Hong Kong 3
MA - Marocco 3
SA - Arabia Saudita 3
VE - Venezuela 3
BO - Bolivia 2
ET - Etiopia 2
HR - Croazia 2
ID - Indonesia 2
LT - Lituania 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
EG - Egitto 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MS - Montserrat 1
NO - Norvegia 1
PK - Pakistan 1
Totale 21.710
Salva come PNG Salva come JPEG
Città #
Southend 2.518
Fairfield 1.168
Jacksonville 771
Chandler 707
Ashburn 676
Wilmington 614
Singapore 611
Woodbridge 579
Princeton 556
Seattle 500
Houston 460
Dong Ket 417
Cambridge 395
Dublin 332
Ann Arbor 331
Nanjing 264
Westminster 255
Padova 241
Bologna 228
Berlin 201
Saint Petersburg 130
Mülheim 126
Santa Clara 126
Lomé 119
Jinan 109
Shenyang 108
San Diego 94
Mahé 90
Medford 90
Milan 88
Nanchang 84
Hebei 81
Beijing 72
Changsha 68
Tokyo 68
Dearborn 54
Sofia 53
Verona 52
Florence 50
Jiaxing 50
Tianjin 49
Norwalk 42
Falls Church 40
Olalla 40
Amman 39
Des Moines 39
Turin 37
Abidjan 36
New York 36
Redmond 36
Los Angeles 35
Hangzhou 34
Boardman 33
Ningbo 32
Helsinki 31
Lanzhou 31
Kunming 28
Zhengzhou 28
Haikou 25
Abeokuta 24
Bühl 23
Guangzhou 19
Brussels 18
Bremen 17
Rome 17
Taizhou 17
Bern 16
London 14
Redwood City 14
Hefei 13
Taiyuan 13
Frankfurt Am Main 11
San Venanzo 11
Chicago 10
Fuzhou 10
Paris 9
Shanghai 8
Costa Mesa 7
Muizenberg 7
Plauen 7
San Jose 7
Anzola Dell'emilia 6
Kiev 6
Mountain View 6
Pune 6
San Francisco 6
Washington 6
Amsterdam 5
Cagliari 5
Genzano Di Roma 5
Las Vegas 5
Lausanne 5
Manila 5
Phoenix 5
São Paulo 5
Toronto 5
Épalinges 5
Azzano San Paolo 4
Fremont 4
Hanover 4
Totale 14.597
Salva come PNG Salva come JPEG
Nome #
Acute onset myopericarditis as unusual presentation of primary HIV infection 188
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. 169
Comparison of the Aptima HIV-1 Quant Dx Assay with the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 v2.0 Test for HIV-1 Viral Load Quantification in Plasma Samples from HIV-1-Infected Patients. 154
Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. 146
Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1 146
A 2-year survey of bacteriologic profile and antimicrobial susceptibility levels of Enterococci in a large Italian teaching hospital. 142
Abacavir-induced febrile agranulocytosis and anaemia. 142
Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy 137
A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection. 137
Atypical progressive multifocal leukoencephalopathy in HIV with a high CD4 count: the use of magnetic resonance imaging plus spectrometry studies 135
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. 133
Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management 133
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 131
Increasing pathomorphism of pulmonary tuberculosis: an observational study of slow clinical, microbiological, and imaging response of lung tuberculosis to specific treatment. Which role for linezolid? 129
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection. 126
Severe peripheral neuropathy with areflexic and flaccid quadriplegia complicating Legionnaires’ disease in an adult patient. 125
Prevalence of renal disease within an urban HIV-infected cohort in northern Italy. 124
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues 122
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz 122
Calcaneal quantitative ultrasound (QUS) and dual X-ray absorptiometry (DXA) bone analysis in adult HIV-positive patients. 121
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 120
Pancreotoxicity of propofol sedation during purulent meningitis. 119
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 119
Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient 119
Chronic hepatitis with diffuse steatosis and slight fibrosis related to etretinate therapy 118
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management 117
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 117
Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. 116
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 114
Bladder carcinoma and HIV infection during the highly active antiretroviral therapy era: a rare, but intriguing association. Two case reports and literature review 114
null 113
Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy 112
Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. 112
Molecular Bases of Osteoporosis in HIV: The Role of the Virus and Antiretroviral Therapy 112
Prevalence And Mutational Pattern Of Occult Hepatitis B Virus Isolated From Liver Tissue Of HIV Infected Patients 112
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen 111
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 111
Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. 111
A prospective comparison of hepatotoxicity of the two currently available non-nucleoside reverse transcriptase inhibitors in a homogeneous case-mix of HIV-infected patients treated for the first time with efavirenz or nevirapine, according to their different baseline conditions 110
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS 110
Aderenza alla terapia antiretrovirale "autogestita" dai pazienti alla metà della posologia giornaliera raccomandata. Inattesa efficacia immunologica e virologica a lungo termine 109
Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy. 107
Epidemiological, clinical and therapeutic features of AIDS-related Mycobacterium kansasii infection during the HIV pandemic: an 11-year follow-up study. 106
Bone mass loss in patients with human immunodeficiency virus type 1 infection: association with male sex and protease inhibitor therapy 105
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. 105
Changing epidemiology of hepatitis A in the Bologna metropolitan area, northern Italy: importance of counselling and prophylactic measures for the male homo/bisexual population. 105
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 105
HIV and kidney: A dangerous liaison 105
Abacavir-lamivudina versus tenofovir-emtricitabina più atazanavir-ritonavir nella semplificazione dell'HAART per dislipidemia 105
Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones. 104
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 104
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir 103
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 103
Chron’s disease, rare association with selective IgA immunodeficiency, and development of life-threatening bacterial infections. 103
Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. 102
Primary Cytomegalovirus infection in otherwise healthy adults with Fever of Unknown Origin: a 3-year prospective survey 102
Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine 102
An observational study of subcutaneous multiple lipomatosis in patients receiving highly active antiretroviral therapy. Possible correlations with metabolic abnormalities and pathogenetic insights 102
Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy 102
Stabilizzazione a lungo termine dell'assetto virologico e immunologico dell'infezione da HIV in un "AIDS Presenter" seguito per oltre vent'anni, nonostante la mancata aderenza alla terapia antiretrovirale 102
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 102
Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS 102
Cardiovascular prevention in HIV-positive individuals on antiretroviral therapy.. The paradigm shift has already happened: Is it time to wake up and realise it? 102
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 102
Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. 101
HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy 101
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 101
AIDS-associated atypical mycobacteriosis other than Mycobacterium avium-intracellulare: a 15-year survey of Mycobacterium kansasii and Mycobacterium xenopi 100
Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-alpha in HIV-infected patients treated with ritonavir-boosted protease inhibitors. 100
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. 99
Legionnaires' disease associated with macular rash: two cases 99
Safety issues about nevirapine administration in HIV-infected pregnant women 99
Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients. 99
Severe pneumococcal meningitis heralding a deep hypogammaglobulinaemia related to common variable immunodeficiency, at the age of 27 years. 99
First-line efavirenz versus lopinavir/ritonavir-based highly active antiretroviral therapy for naïve patients. 98
An extremely different dysmetabolic profile between the two available nonucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. 97
Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. 97
Antiretroviral therapy voluntarily taken at half-dosage, but fully effective after 6-10 years: a provocative issue for adherence requirements. Case report 97
Adenocarcinoma vescicale in corso di infezione da HIV. Percorso diagnostico, clinico e terapeutico di tre casi clinici 96
Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients. 96
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection. 95
Extra-western European citizens in the setting of infectious diseases: a rapidly evolving trend in northern Italy. 95
AIDS e patologie tumorali multiple come condizioni emergenti in epoca di terapia antiretrovirale altamente attiva (HAART) 95
Polyunsaturated ethyl esters on n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. 94
Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study 94
Severe brain co-infection with Cryptococcus neoformans and Mycobacterium tuberculosis in a young, otherwise healthy student recently immigrated from China 93
Measles outbreak in the city of Bologna, December 2007 to May 2008 93
A case-control study of HIV-associated pancreatic abnormalities during HAART era. Focus on emerging risk factors and specific management. 93
Membranoproliferative glomerulonephritis associated with human immunodeficiency virus, hepatitis B and hepatitis C virus coinfection: case report and literature review. 92
HIV infection and the pancreas: risk factors and potential management guidelines 92
Antibiotic therapy for infective endocarditis in childhood 92
Human herpesvirus-8-related Kaposi’s sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin. 92
Renal toxicity associated with antiretroviral therapy 92
AIDS-associated atypical mycobacteriosis other than Mycobacterium avium-intracellulare: a 14-year survey of Mycobacterium xenopi and Mycobacterium kansasii 91
Antiretroviral treatment and gynecomastia: which correlations? 90
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients 90
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 90
Concurrence of two different opportunistic mycoses complicated by visceral dissemination diagnosed in "AIDS Presenter" patients: candidiasis and cryptococcosis 89
Raltegravir plus lamivudine as 'maintenance therapy' in suppressed HIV-1-infected patients in real-life settings. 89
Methicillin-resistant staphylococci still susceptible to non-beta-lactam antibiotics. What clinical implications in nosocomially-acquired infections? 88
Totale 10.956
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.336
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.336
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.636 0 0 137 394 457 545 666 834 636 395 131 441
2020/20213.305 834 284 65 175 45 194 40 209 198 231 177 853
2021/20224.312 402 215 284 406 405 262 77 331 146 349 732 703
2022/20233.746 467 596 209 473 237 225 127 188 621 118 361 124
2023/2024867 72 156 63 98 66 158 51 62 25 64 23 29
2024/20251.182 118 901 163 0 0 0 0 0 0 0 0 0
Totale 22.128